Cargando…
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
BRCA and poly-ADP ribose polymerase (PARP) regulate pathways of DNA repair. Due to the accumulation of mutations introduced by error-prone DNA repair, breast and ovarian cancers develop in the setting of BRCA deficiency. A series of recent clinical trials has tested the use of PARP inhibition as a t...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Faculty of 1000 Ltd
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948351/ https://www.ncbi.nlm.nih.gov/pubmed/20948822 http://dx.doi.org/10.3410/B2-10 |